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Midkine (MK) is a heparin-binding growth factor found as the
product of a retinoic acid-responsive gene (Kadomatsu et al,
1988). It has 45% sequence identity to pleiotrophin
(PTN)/heparin-binding growth-associated molecule (HB-GAM),
and together these molecules comprise a family of heparin-binding
growth factors (Li et al, 1990; Merenmies and Rauvala, 1990).
MK has diverse activities, for example it enhances neuronal cell
survival, neurite outgrowth and fibrinolysis (Michikawa et al,
1993; Muramatsu et al, 1993; Kojima et al, 1995). MK as well as
PTN/HB-GAM have been implicated in carcinogenesis (Kurtz et
al, 1995). MK transforms NIH3T3 cells (Kadomatsu et al, 1997)
and enhances angiogenic activities of tumour cells (Choudhuri et
al, 1997). It is highly expressed at both mRNA and protein levels
in premalignant stages in human colorectal carcinomas (Ye et al,
1999). MK mRNA and protein expression are frequently elevated
in many human carcinomas, such as breast, lung, oesophageal,
stomach, colorectal, liver, ovary and urinary bladder carcinomas,
prostate carcinomas, glioblastomas, neuroblastomas and Wilms’
tumours (Tsutsui et al, 1993; Garver et al, 1994; Aridome et al,
1995; Nakagawara et al, 1995; O’Brien et al, 1996; Mishima et al,
1997; Konishi et al, 1999). In neuroblastomas, glioblastomas and
urinary bladder carcinomas, high levels of MK expression are
correlated with poor prognosis (Nakagawara et al, 1995; O’Brien
et al, 1996; Mishima et al, 1997). Since MK is a secreted protein,
serum MK levels are expected to increase when tumour tissues
express abundant MK. Although our preliminary studies yielded
promising results, they were not conclusive because of the limited
numbers of samples (Song et al, 1997). In the present study, we
employed a new and more convenient assay method and analysed
samples from 150 cancer patients and 135 controls.
MATERIALS AND METHODS
Human MK and antibodies
To generate human MK protein, an expression vector for yeast
(Pichia pastoris GS115; Research Corporation Technologies) was
constructed by inserting a cDNA fragment covering the open
reading frame of human MK into pHIL-D4 (In Vitrogen).
Following transfection of the expression vector into yeast, selec-
tion with histidine and G418 was carried out. The human MK
protein was purified from yeast by anion exchange chromatog-
raphy and affinity chromatography on a heparin column. The puri-
fied protein exhibited neurotrophic activity comparable with that
of L cell-produced mouse MK (Muramatsu et al, 1993).
Rabbit and chicken antibodies were raised against the yeast-
produced human MK, and were precipitated with ammonium
sulphate, and affinity purified with a human MK-column. These
antibodies specifically detected human MK on Western blotting
analysis (data not shown). Peroxidase labelling of the antibodies
was carried out as described (Ishikawa et al, 1993).
Serum samples
Sera were obtained from blood collected from normal individuals (n
= 135; male = 94; female = 41; ages 20–29 = 31; 30–39 = 59; 40–49
= 25; 50–59 = 11; > 60 = 9; median value = 34; average value =
37.6), cancer patients (n = 150; male = 96; female = 54; ages 26–85;
median value = 64; average value = 62.9) (Table 1) and other
patients with or without inflammation (n = 80; male = 35; female =
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Table 1 Clinical characteristics of tumours
n
Oesophageal carcinoma
Histology
Well differentiated squamous cell carcinoma 6
Moderately differentiated squamous cell carcinoma 5
Poorly differentiated squamous cell carcinoma 3
Squamous cell carcinoma 2
Adenosquamous cell carcinoma 2
Stage
I5
II 4
III 6
IV 2
Recurrence 1
Size
≤ 2c m 0
2–5 cm 10
≥ 5c m 8
Gastric carcinoma
Histology
Well differentiated tubular adenocarcinoma 6
Well to moderately differentiated tubular adenocarcinoma 1
Moderately differentiated tubular adenocarcinoma 5
Poorly differentiated adenocarcinoma 9
Mucinous adenocarcinoma 1
Adenocarcinoma (unclassified) 2
signet-ring cell carcinoma 6
Stage
I1 8
II 2
III 6
IV 4
Size 
≤ 2c m 5
2–5 cm 12
≥ 5c m 1 1
No surgery 2
Duodenal carcinoma (adenocarcinoma)
Stage
I0
II 0
III 2
IV 0
Size
≤ 2c m 0
2–5 cm 1
≥ 5c m 1
Colon carcinoma
Histology
Well differentiated adenocarcinoma 10
Well to moderately differentiated adenocarcinoma 1
Moderately differentiated adenocarcinoma 6
Mucinous cystadenocarcinoma 1
Adenocarcinoma (unclassified) 6
Focal carcinoma in tubular adenoma 1
Stage
01
I4
II 4
III 5
IV 5
Recurrence 6
Size
≤ 2c m 3
2–5 cm 10
≥ 5c m 1 1
No surgery 1
Hepatocellular carcinoma
Stage
I0
II 11
III 9
IV 2
Recurrence 3
Size
≤ 2c m 3
2–5 cm 15
≥ 5c m 6
No surgery 1
Bile-duct and gallbladder carcinoma
Histology
Well differentiated adenocarcinoma 2
Moderately differentiated adenocarcinoma 4
Poorly to moderately differentiated adenocarcinoma 1
Poorly differentiated adenocarcinoma 1
Tubular adenocarcinoma 1
Cholangiocarcinoma 1
No surgery 2
Stage
I2
II 4
III 4
IV 2
Size
≤ 2c m 3
2–5 cm 5
≥ 5 cm 2
No surgery 2
Pancreatic carcinoma
Histology
Invasive ductal carcinoma 2
Adenocarcinoma 4
Papillary adenocarcinoma 2
Anaplastic ductal carcinoma 1
Stage
I5
II 0
III 1
IV 3
Size
≤ 2c m 2
2–5 cm 3
≥ 5c m 1
No surgery 3
Thyroid carcinoma (papillary carcinoma)
Stage
I0
II 4
III 1
IV 0
Size
≤ 2c m 3
2–5 cm 2
≥ 5c m 0
Lung carcinoma
Histology
Well differentiated adenocarcinoma 3
Moderately differentiated adenocarcinoma 9
Poorly differentiated adenocarcinoma 1
Adenocarcinoma (unclassified) 1
Small cell carcinoma 1
Squamous cell carcinoma 3
Papillary adenocarcinoma with large cell carcinoma 1
Stage
I1 1
II 1
III 6
IV 1
Size
≤ 2c m 3
2–5 cm 14
≥ 5c m 245; ages 20–70), and were immediately frozen and kept at –20° C
until assay. We regard those with C-reactive protein (CRP) values >
0.1 mg ml–1 as those with inflammation and those with CRP values
< 0.1 mg ml–1 as those without inflammation. Except otherwise
specified, sera from cancer patients were obtained before surgical or
other treatment. Informed consent was obtained from patients and
normal individuals according to the guidelines approved by Ethical
Committee of the University Hospitals. Stage of carcinoma was
determined by the TNM classification. C-reactive protein level was
determined by latex aggregation method.
Enzyme-linked immunoassay (EIA) for human MK
As a standard method, 50 µ l of rabbit anti-human MK antibodies at
a concentration of 5.5 µ g ml–1 in phosphate-buffered saline (PBS)
was adsorbed onto the wells of microtiter plates (Polysorp plates,
Nunc) for 16 h at room temperature. After washing with 1% Tween
20 in PBS, the wells were blocked with 150 µ l of 0.5% BSA in PBS
for 2 h at 37° C. On the other hand, control human MK samples or
serum samples (10 µ l each) were mixed with 100 µ l of 50 mM Tris
HCl (pH 8.4), 0.5 M KCl, 0.5% bovine serum albumin (BSA),
0.01% Microcide I (aMReSCO, Solon, Ohio, USA) containing
peroxidase-labelled chicken anti-human MK antibodies (0.1 µ g
ml–1). Aliquots of 50 µ l of this mixture were added into the wells of
microtiter plates prepared as described above. After incubation for
1 h at room temperature, the wells were washed five times with 1%
Tween 20 in PBS. Aliquots of 100 µ l of a substrate solution
(tetramethylbenzidine at 0.5 mg ml–1 in Dako S1600, Dako, USA)
were added into the wells and the plates were incubated for 30 min
at room temperature. The reaction was stopped by adding 100 µ l of
2 N sulphuric acid, and OD450 was detected using a multiplate
reader (Model 3550, BioRad).
Statistics
Statistical significance was evaluated by Mann–Whitney U test.
Correlation was examined by Spearman’s correlation coefficient
by rank with Z conversion of Fisher’s r.
RESULTS
EIA for MK employing two polyclonal antibodies from
different species
The newly developed EIA for human MK employed a combina-
tion of two anti-human MK antibodies from different species
(rabbit and chicken). This procedure increased the sensitivity of
the detection of human MK, as compared with the use of rabbit
antibodies alone (Figure 1A). No cross-reactivity was observed
with human pleiotrophin, which shows 45% sequence identity to
human MK (Figure 1B).
Serum MK levels of normal controls and cancer
patients
Using this EIA, we determined serum MK levels of 135 control
individuals. Normal serum MK level was 0.154 ± 0.076 ng ml–1
(mean  ± SD), and in no case did the value reach 0.5 ng ml–1
(Figure 2). Thus 0.5 ng ml–1 was set as the cut-off value. There
were no significant differences in MK values between men and
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Breast carcinoma
Table 1 continued
n
Histology
Invasive ductal carcinoma 4
Noninvasive ductal carcinoma 1
Stage
I1
II 3
III 0
IV 1
Size
≤ 2c m 1
2–5 cm 3
≥ 5 cm (1) 1
Rabbit-Rabbit
Rabbit-Chicken
3.0
2.5
2.0
1.5
1.0
0.5
0.0
02468 1 0 1 2
O
D
4
5
0
O
D
4
5
0
MK
PTN
2.0
1.5
1.0
0.5
0.0
0 1 2 3 4 5
MK (ng ml–1)
MK (ng ml–1)
A
B
Figure 1 Enzyme-linked immunoassay for human MK. A The combination
of rabbit and chicken antibodies showed higher sensitivity than use of rabbit
antibodies alone. Each point was the average of five assays ± SD. B
Absence of cross-reactivity with human pleiotrophin. The EIA for human MK
barely detected human pleiotrophinwomen, or among age groups: As an example, in the normal
control with ages > 50 (n = 20, average age = 60), the MK value
was 0.184 ± 0.111 ng ml–1. Serum MK levels of 150 cancer
patients showed a profile significantly different from that of
normal controls (P < 0.001, Mann–Whitney U test) (Figure 3).
Eighty-seven percent of the patients had a value higher than 0.5
ng ml–1.
As shown in Figure 3, the increase in serum MK level was
observed in all ten types of carcinomas examined. In addition,
each tissue type showed a similar profile of serum MK level,
suggesting that the profile of increased serum MK level was
general rather than tissue-specific.
In case of gastric carcinomas and lung carcinomas, sera from
patients with carcinomas at early stages were available in large
numbers to test whether serum MK level was increased at the early
stages. We found that statistically significant increase in MK level
was observed even at stage I of these carcinomas (Table 2).
Although the average value of serum MK was lower in stage I than
in stages II–IV, the differences were not statistically significant in
both gastric carcinoma and lung carcinoma.
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Figure 2 Serum MK level of normal controls. Each number on the x-axis
indicates the upper value of serum MK level in increments of 0.05 ng ml–1
Esophageal **
n = 18, 0.71 (0.47–1.28)
Gastric **
n = 30, 0.77 (0.58–1.24)
Duodenal *
n = 2, 0.71 (0.46–0.96)
Colon **
n = 25, 0.97 (0.72–1.70)
Hepatocellular **
n = 25, 1.22 (0.83–5.48)
Bile–duct **
n = 12, 1.33 (1.02–2.28)
Pancreatic **
n = 9, 0.66 (0.55–0.77)
Thyroid **
n = 5, 0.74 (0.65–1.14)
Lung **
n = 19, 1.19 (0.60–2.44)
Breast **
n = 5, 0.72 (0.58–2.06)
0.15 0.50 1 2 3 45
MK (ng ml–1)
Figure 3 Comparison of serum MK levels in different types of carcinoma. Solid line at left shows the average value of serum MK in normal individuals. Dotted
line shows cut off value of 0.50 ng ml–1. Number of cases and the median value with 25th and 75th percentiles are shown under the name of each carcinoma.
(Mann-Whitney U-test *P < 0.05; **P < 0.01) Bile-duct carcinoma includes two cases of gallbladder carcinoma
Table 2 Serum MK levels in patients with gastric carcinomas and lung
carcinomas at different stages
Serum MK (ng ml–1)
Stage
I II–IV
Gastric carcinoma 0.73 0.93
(n = 31) (n = 18) (n = 13)
Lung carcinoma 1.21 2.05
(n = 21) (n = 11) (n = 8)
All values larger than the average normal serum value (P < 0.01,
Mann–Whitney U test)Furthermore, when we compared MK values between patients
with different tumour sizes, i.e. > 5 cm diameter, 2–5 cm and < 5
cm, there were no significant differences between the groups.
The effects of surgical removal of tumours on serum MK values
were examined in five patients with hepatocellular carcinoma. In
four cases, significant decrease of the values was found after
tumour removal (Figure 4).
Finally, to determine whether serum MK level was affected by
inflammation, we determined serum levels of both CRP and MK
of 80 outpatients with inflammation (CRP value > 0.1 mg dl–1) or
without inflammation. However, as shown in Figure 5, there was
no or weak correlation between these two factors (P = 0.0762,
correlation coefficient 0.331). Also using the same specimens, we
determined leukocyte counts and found no correlation with MK
serum levels (P = 0.5697, correlation coefficient – 0.110).
DISCUSSION
We developed a new procedure for EIA of human MK using rabbit
and chicken antibodies. Chicken and mouse MKs show 73% iden-
tity, whereas mouse and human MK show 87% identity (Raulais et
al, 1991). This sequence divergence between mammals and birds
suggests that chickens immunized with human MK could produce
antibodies that recognize more epitopes, including epitopes
different from those recognized by the rabbit. Indeed, a combina-
tion of chicken and rabbit anti-human MK antibodies exhibited a
much higher sensitivity in the detection of human MK than rabbit
antibodies alone; the major epitopes recognized by chicken anti-
bodies are probably different from those recognized by rabbit
antibodies. In EIA for MK reported previously (Muramatsu 
et al, 1996), we employed rabbit anti-MK antibodies and their
biotinylated forms as well as avidin-β -galactosidase and a fluoro-
genic substrate, 4-methylumbelliferyl-β -D-galactoside. As
compared to the previous method, the present EIA was advanta-
geous in that it uses an ordinary colourimetric detection system
that is more convenient for clinical use.
Using this procedure, we analysed sera from a large number of
patients and found that serum MK levels were elevated in most of
the cancer patients examined (87%). The ratio of patients with
increased serum MK levels to total cancer patients examined
agreed with that of patients with increased MK expression in
tumour tissues reported previously (Tsutsui et al, 1993; Garver et
al, 1994; Aridome et al, 1995; Nakagawara et al, 1995; O’Brien et
al, 1996; Mishima et al, 1997; Song et al, 1997; Ye et al, 1999).
Thus, MK expressed in carcinomatous tissues is probably secreted
into the bloodstream, leading to an increase in serum MK level in
cancer patients. It is notable that the increased expression of MK in
carcinomatous tissues and the elevated serum MK levels in cancer
patients did not show specification for a particular tissue. This is
reminiscent of the case of p53 mutations in human carcinomas,
suggesting the biological importance of MK in carcinogenesis.
The role of MK in carcinogenesis and/or tumour progression, as
indicated by its transforming (Kadomatsu et al, 1997) and angio-
genic (Choudhuri et al, 1997) activities, is consistent with this
assumption.
Recently, MK has been shown to have anti-apoptotic activity to
embryonic neurons (Michikawa et al, 1993, Owada et al 1999) and
to Wilms’ tumour cells (Qi et al, 2000). MK also promotes migra-
tion of various cells such as embryonic neurons (Maeda et al,
1999), neutrophils (Takada et al, 1997) and macrophages (Horiba
et al, 2000). These two activities of MK might be helpful in
survival and invasion of tumour cells.
In the majority of cases, the serum MK levels decreased after
surgical removal of hepatocellular carcinomas, as is expected from
its nature as a tumour marker. Future study is required to know
whether the value decreases in all types of tumours. The serum
MK values were not significantly dependent on stages and on
tumour sizes. The present study also revealed that MK values are
not significantly correlated with markers of inflammation, namely
CRP values and leukocyte counts. In non-malignant hepatic
diseases, 14.5% of patients showed elevated serum MK values
(more than 0.5 ng ml–1) (Song et al, 1997). Although the frequency
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Figure 4 Effects of tumour removal on serum MK values. MK values were
determined before the surgery ( ) or 7 days after the surgery (  ). Number
indicates the case number
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Figure 5 Relation between C-reactive protein (CRP) and MK. Serum levels
of C-reactive protein and MK were examined in 80 patients with or without
inflammation. There was no or weak correlation between these two factorsof elevated cases is much less as compared to be patients with
carcinomas, it should be kept in mind that in certain restricted
cases of non-malignant diseases, serum MK values might become
elevated.
We previously found that MK expression was increased in the
pre-cancerous tissue at adenoma stages of human colorectal
carcinogenesis (Ye et al, 1999). MK was also detected in latent
prostate cancers and prostatic intra-epithelial neoplasia (Konishi et
al, 1999). These findings imply that MK may be useful in
detecting certain carcinomas at early stages. Indeed, in the cases of
gastric carcinoma and lung carcinoma, elevated serum MK level
was found even at stage I. It is of significant interest whether
determination of serum MK could serve as a marker in detection
of these carcinomas at the early stages.
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